ClinConnect ClinConnect Logo
Search / Trial NCT01750203

Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay

Launched by SYSTAGENIX WOUND MANAGEMENT · Dec 12, 2012

Trial Information

Current as of May 22, 2025

Completed

Keywords

Diabetic Foot Ulcers, Venous Leg Ulcers, Pressure Sores, Acute Wounds

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject has presented to participating study site with a wound(s) suspected to be infected, as determined by the Investigator and/ or study staff - defined as one that through clinical judgment has questionable infection status, and /or shows three or more of the NERDS or STONES signs of infection);
  • Subject has presented to participating study site with a wound(s) suspected not to be infected, as determined by the Investigator and/ or study staff - defined as one that does not show three or more of the NERDS or STONES signs of infection.
  • Subject is 18 years of age or older.
  • Subject agrees to complete all aspects of the study and provides Informed Consent
  • Exclusion Criteria:
  • Subject is less than 18 years of age.
  • Target wound contains a malignancy
  • Subject has hypersensitivity of the wound or painful wound surface which prevents touching/swabbing of the wound surface.
  • Subject is confirmed to be positive for HIV or hepatitis.
  • Subject is unable or unwilling to provide informed consent.
  • Subjects deemed inappropriate for the study by the site's Principal Investigator.

About Systagenix Wound Management

Systagenix Wound Management is a leading global company dedicated to advancing wound care through innovative products and evidence-based solutions. With a strong focus on enhancing patient outcomes, Systagenix develops and manufactures a comprehensive range of advanced wound dressings and therapeutic technologies. The organization is committed to rigorous clinical research and trials that support the efficacy and safety of its products, ensuring they meet the highest standards in the healthcare industry. By collaborating with healthcare professionals and leveraging cutting-edge science, Systagenix aims to improve the quality of life for patients with complex wounds worldwide.

Locations

Tulsa, Oklahoma, United States

Patients applied

0 patients applied

Trial Officials

Tom Serena, MD

Principal Investigator

SerenaGroup, Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials